The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy

• Status: Completed
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

1. To determine the influencing factors of modified electroconvulsive therapy (MECT);

2. To determine the influencing factors and reversibility of the cognitive impairment caused by MECT;

3. To determine the duration of efficacy of MECT and its affecting factors.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Collaborators: Huashan Hospital; Tongji Hospital
• Treatments: Etomidate; Propofol

Criteria

Inclusion Criteria:

• Aged over 18 years (when informed consent was got), male or female

• Meet International Classification of Diseases-10(ICD-10) diagnostic criteria for depression

• Scored 18 or above on the HAM-D Scale which included 17 items

• Clinical Global Impression(CGI)-severity score ≥ 4

• Provided written informed consent

Exclusion Criteria:

• Any depressive disorders not due to major depressive disorder

• Meet other diagnosis criteria in Diagnostic and Statistical Manual of Mental Disorders-IV-Test Revision(DSM-IV-TR) Axis I

• With a history of acute or chronic renal failure, liver cirrhosis or active hepatopathy

• With clinically significant abnormal results of laboratory test, which are considered to have impact on treatment efficacy and the safety of participants

• With a history of severe or unstable physical disease including nervous system disease and myocardial infarction

• Undergoing alcoholism or alcohol (or substance) abuse during 30 days or 6 months before the trial

• With no response to previous ECT treatment

• Received transcranial magnetic stimulation treatment in the last 6 months

• Allergic to propofol, etomidate and succinylcholine chloride

• During pregnancy or lactation

• With a history of stroke in the last month

• Enrolled in any other clinical trial 30 days prior to the baseline